Koers Flex Pharma Inc Nasdaq
Aandelen
US33938A1051
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 2,14 mln. 2 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -21 mln. -19,64 mln. | Nettowinst (verlies) 2025 * | -23 mln. -21,51 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,02
x | K/w-verhouding 2025 * |
-0,02
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 93,92% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19-07-19 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 10-09-19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19-07-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19-07-19 |
Paul Lammers
BRD | Director/Board Member | 66 | 19-07-19 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 19-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |